Condition: Advanced Solid Tumor · Lymphoma · NSCLC · Sponsor: Betta Pharmaceuticals Co., Ltd.
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
This description comes directly from the study's public registry record.
Yuankai Shi, Ph.D · 010-67781331 · syuankaipumc@126.com
Always discuss trial participation with your own doctor first.
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Chaoyang, Beijing Municipality, China | Recruiting |
| Cangzhou Central Hospital | Cangzhou, Hebei, China | Completed |
| Tianjin Cancer Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05341557